Internet Archive Scholar

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels*

Edward A. Panacek, John C. Marshall, Timothy E. Albertson, David H. Johnson, Steven Johnson, Rodger D. MacArthur, Mark Miller, William T. Barchuk, Steven Fischkoff, Martin Kaul, Leah Teoh, Lori Van Meter (+4 others)
2004 Critical Care Medicine  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (904.1 kB)
https://web.archive.org/web/20170809142343/http://www.ccmpitt.com/ebm/core_evidence/Sepsis-%20anti%20TNF%20antibody%20%202004.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL. The file type is application/pdf.

doi:10.1097/01.ccm.0000145229.59014.6c fatcat:rfc6lrdxfvcqfhb3efn7ei2pvu
Citation

Edward A. Panacek, John C. Marshall, Timothy E. Albertson, David H. Johnson, Steven Johnson, Rodger D. MacArthur, Mark Miller, William T. Barchuk, Steven Fischkoff, Martin Kaul, Leah Teoh, Lori Van Meter, Lothar Daum, Stanley Lemeshow, Gregory Hicklin, Christopher Doig. "Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels*." Critical Care Medicine 32.11 (2004) 2173-2182